Aptinyx's pain compound misses Phase II endpoint

Aptinyx Inc. (NASDAQ:APTX) said all three doses of NYX-2925 missed the primary endpoint in a Phase II trial to treat pain associated with diabetic peripheral neuropathy.

The primary endpoint measured mean change in average daily pain scores on

Read the full 375 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE